External composition

An external composition with ufenamate, lidocaine, glycyrrhetinic acid, diphenhydramine, and an antibacterial agent addresses shaving-induced skin inflammation, offering relief and improved skin health in sensitive areas.

JP7587933B2Active Publication Date: 2024-11-21KOBAYASHI PHARMA CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020101676
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-06-11
Publication Date
2024-11-21
Estimated Expiration
2040-06-11

AI Technical Summary

Technical Problem

Shaving causes skin inflammation, particularly in sensitive areas like the genitals, due to contact stimulation and hair tip irritation, leading to discomfort and difficulty in handling shaving equipment.

Method used

An external composition containing ufenamate, lidocaine, glycyrrhetinic acid, diphenhydramine, tocopherol, and an antibacterial agent, formulated as a cream or lotion, to alleviate skin inflammation post-shaving.

Benefits of technology

The composition effectively reduces skin inflammation and irritation, providing relief and improving skin health in sensitive areas.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587933000001
    Figure 0007587933000001
  • Figure 0007587933000002
    Figure 0007587933000002
Patent Text Reader

Abstract

To provide an external composition used for improving skin inflammation after shaving.SOLUTION: The external composition comprises (A) ufenamate and (B) lidocaine and / or a salt thereof. The external composition is effective in improving skin inflammation after shaving.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition for external use used to improve inflammation of the skin after shaving. [Background technology]

[0002] In recent years, with the growing awareness of beauty, body hair removal has become common among a wide range of people. Methods for removing body hair are usually epilation, shaving, and depilation, and epilation is widely performed by specialized institutions (medical institutions and beauty salons) using specialized equipment.

[0003] On the other hand, the method of hair removal that still accounts for the largest proportion is self-treatment by shaving. Although self-treatment may involve the use of home appliances, tweezers, hair removal cosmetics, etc., the convenience of shaving far surpasses other methods. Furthermore, the reality is that shaving is the only method available for self-treatment of delicate areas (lower abdomen, vulva, anus).

[0004] During shaving, the skin is subject to contact stimuli such as contact with the blade of the shaving tool and friction from protective equipment such as blade guards, making it prone to inflammation after shaving. Furthermore, the tips of shaved body hair have corners, and the hair grows quickly, making the surrounding skin more susceptible to injury, which also causes inflammation. In general, skin inflammation due to shaving is relatively low in the skin of the arms and legs (Non-Patent Document 1), but the skin of the pubic area in particular is thinner and more sensitive than the skin of other parts, has thicker body hair than other parts, is difficult to handle with the shaving tool, is easily irritated, and is constantly exposed to a harsh, humid environment due to pressure from underwear after shaving, so the risk of inflammation due to shaving is extremely high. For this reason, problems caused by self-shaving are endless. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] J. Soc. Cosmet. Chem. Jpn. 44 (4) 298-303 (2010) Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide a composition for external use that can be used to improve skin inflammation after shaving. [Means for solving the problem]

[0007] As a result of intensive research, the present inventors have found that a composition for external use containing ufenamate and lidocaine shows excellent effects in improving inflammation of the skin after shaving. Based on this finding, the present invention has been completed through further research.

[0008] That is, the present invention provides the following aspects. Item 1. A composition for external use comprising (A) ufenamate and (B) lidocaine and / or a salt thereof, which is used to improve skin inflammation after shaving. Item 2. The external composition according to Item 1, which is applied to inflammation of the skin in the lower abdomen, vulva, and / or anal area. Item 3. The composition for external use according to Item 1 or 2, which is applied to inflammation not accompanied by itching. Item 4. The composition for external use according to any one of Items 1 to 3, further comprising (C) glycyrrhetinic acid, a derivative of glycyrrhetinic acid, and / or a salt thereof, (D) diphenhydramine and / or a salt thereof, (E) tocopherol and / or a derivative thereof, and / or (F) an antibacterial or bactericidal agent. Effect of the Invention

[0009] According to the present invention, there is provided a composition for external use used to improve skin inflammation after shaving. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The topical composition of the present invention contains (A) ufenamate (hereinafter also referred to as "component (A)") and (B) lidocaine and / or a salt thereof (hereinafter also referred to as "component (B)" or "lidocaines"), and is characterized in that it is used to improve inflammation of the skin after shaving. The topical composition of the present invention may further contain (C) glycyrrhetinic acid, a derivative of glycyrrhetinic acid, and / or a salt thereof (hereinafter also referred to as "component (C)" or "glycyrrhetinic acids"), (D) diphenhydramine and / or a salt thereof (hereinafter also referred to as "component (D)" or "diphenhydramines"), (E) tocopherol and / or a derivative thereof (hereinafter also referred to as "component (E)" or "tocopherols"), and / or (F) a quaternary ammonium antibacterial agent (hereinafter also referred to as "component (F)"). From the viewpoint of further improving the effect of improving skin inflammation after shaving, the topical composition of the present invention preferably contains component (A), component (B), component (C), component (D), component (E), and component (F). The topical composition of the present invention will be described in detail below.

[0011] (A) Ufenamart The topical composition of the present invention contains ufenamate as component (A). Ufenamate is also called butyl flufenamate and is a known drug as a fat-soluble nonsteroidal anti-inflammatory drug. Component (A) alone does not have much effect on improving skin inflammation after shaving, but the topical composition of the present invention can exhibit an excellent effect on improving skin inflammation after shaving.

[0012] In the topical composition of the present invention, the content of component (A) is appropriately set depending on the medicinal effect to be exerted, and may be, for example, 1 to 20% by weight. From the viewpoint of further improving the effect of improving skin inflammation after shaving, the content of component (A) in the topical composition of the present invention is preferably 3 to 6% by weight, and more preferably 4.5 to 5.5% by weight.

[0013] (B) Lidocaines The topical composition of the present invention contains lidocaine and / or a salt thereof as component (B). Lidocaine, also known as xylocaine, is a known drug known to have a local anesthetic effect. Component (B) is a local anesthetic that does not improve inflammation by itself, but when combined with component (A), it dramatically improves the improving effect on skin inflammation after shaving.

[0014] The salt of lidocaine is not particularly limited as long as it is pharma- ceutical acceptable, and specific examples include inorganic acid salts such as hydrochloride.

[0015] In the composition for external use of the present invention, one of lidocaine and its salts may be selected and used alone, or two or more of them may be used in combination. Among lidocaine and its salts, lidocaine is preferred from the viewpoint of further improving the effect of improving skin inflammation after shaving.

[0016] The content of component (B) in the topical composition of the present invention may be appropriately set depending on the medicinal effect to be imparted, and may be, for example, 0.1 to 5 wt. %, preferably 0.2 to 2 wt. %, and more preferably 0.5 to 1.5 wt. % of the total amount of component (B).

[0017] In the topical composition of the present invention, the ratio of component (B) to component (A) is determined depending on the respective contents of components (A) and (B). For example, the total amount of component (B) per 1 part by weight of component (A) is, for example, 0.01 to 1.5 parts by weight, preferably 0.05 to 1 part by weight, and more preferably 0.1 to 0.5 parts by weight.

[0018] (C) Glycyrrhetinic acid The topical composition of the present invention may contain glycyrrhetinic acid, a derivative thereof, and / or a salt thereof as component (C) from the viewpoint of further improving the effect of improving skin inflammation after shaving.

[0019] Glycyrrhetinic acid is a known drug that is known to have anti-inflammatory and anti-allergic effects.

[0020] The derivatives of glycyrrhetinic acid are not particularly limited as long as they are pharma- ceutically acceptable, but specific examples include pyridoxine glycyrrhetinate, stearyl glycyrrhetinate, glyceryl glycyrrhetinate, monoglucuronide glycyrrhetinate, etc. These derivatives of glycyrrhetinic acid may be used alone or in combination of two or more.

[0021] The salt of glycyrrhetinic acid and / or its derivative is not particularly limited as long as it is pharma- ceutically acceptable, and specifically includes alkali metal salts such as sodium salts and potassium salts; ammonium salts, etc. These salts may be used alone or in combination of two or more.

[0022] In the topical composition of the present invention, one or more of glycyrrhetinic acid, salts of glycyrrhetinic acid, derivatives of glycyrrhetinic acid, and salts of derivatives of glycyrrhetinic acid may be selected as component (C) and used, or two or more may be used in combination.

[0023] Of these components (C), glycyrrhetinic acid is preferred from the viewpoint of further improving the effect of improving skin inflammation after shaving.

[0024] In the topical composition of the present invention, the content of component (C) is not particularly limited and may be appropriately set depending on the medicinal effect to be imparted, and the like. For example, the total amount of component (C) is 0.05 to 5 wt.%, and from the viewpoint of further improving the effect of improving skin inflammation after shaving, the content is preferably 0.1 to 1 wt.%, and more preferably 0.2 to 0.5 wt.%.

[0025] In the topical composition of the present invention, the ratio of component (C) to component (A) is determined depending on the respective contents of components (A) and (C), but may be, for example, a total amount of component (C) of 0.01 to 0.9 parts by weight per part by weight of component (A). From the viewpoint of further improving the effect of improving skin inflammation after shaving, a total amount of component (C) of preferably 0.03 to 0.5 parts by weight, more preferably 0.05 to 0.1 parts by weight per part by weight of component (A).

[0026] (D) Diphenhydramines The topical composition of the present invention may contain diphenhydramine and / or a salt thereof as component (D) in order to further improve the effect of improving skin inflammation after shaving. Diphenhydramine is a known drug known to have an antihistamine effect. Component (D) alone has almost no effect of improving skin inflammation after shaving, but when combined with components (A) and (B), it is possible to significantly improve the effect of improving skin inflammation after shaving.

[0027] The salt of diphenhydramine is not particularly limited as long as it is pharma- ceutically acceptable, and specific examples thereof include acid addition salts such as hydrochloride, citrate, succinate, tartrate, fumarate, maleate, salicylate, diphenyl disulfonate, tannate, lauryl sulfate, sulfate, etc. These salts may be used alone or in combination of two or more.

[0028] In the topical composition of the present invention, one type of diphenhydramine and its salts may be selected and used as component (D), or two or more types may be used in combination.

[0029] Among these components (D), diphenhydramine is preferred from the viewpoint of further improving the effect of improving skin inflammation after shaving.

[0030] In the topical composition of the present invention, the content of component (D) is not particularly limited, and may be, for example, 0.1 to 5% by weight of the total amount of component (D). From the viewpoint of further improving the effect of improving skin inflammation after shaving, the content of component (D) in the topical composition of the present invention is preferably 0.3 to 2% by weight, more preferably 0.5 to 1.5% by weight.

[0031] In the topical composition of the present invention, the ratio of component (D) to component (A) is determined depending on the respective contents of components (A) and (D), but for example, the total amount of component (D) is 0.01 to 1.2 parts by weight per part by weight of component (A). From the viewpoint of further improving the effect of improving skin inflammation after shaving, the total amount of component (D) is preferably 0.05 to 0.8 parts by weight, more preferably 0.1 to 0.5 parts by weight, per part by weight of component (A).

[0032] (E) Tocopherols The topical composition of the present invention may further contain tocopherol and / or a derivative thereof as component (E) from the viewpoint of further improving the effect of improving skin inflammation after shaving.

[0033] Tocopherol is a known compound known as vitamin E. Tocopherol may be any of d-, l-, and dl-forms, with dl-form being preferred. Tocopherol may be any of α-, β-, γ-, and δ-forms, with α-form being preferred.

[0034] The tocopherol derivative is not particularly limited as long as it is pharma- ceutically acceptable, and examples thereof include esters with carboxylic acids such as acetic acid, nicotinic acid, succinic acid, and the like, diesters with phosphoric acid, etc. Among these tocopherol derivatives, from the viewpoint of further improving the effect of improving skin inflammation after shaving, preferred are esters with carboxylic acids, and more preferred is tocopherol acetate.

[0035] The tocopherol derivative may be any of d-, l-, or dl-forms, with the dl-form being preferred.The tocopherol derivative may be any of α-, β-, γ-, or δ-forms, with the α-form being preferred.

[0036] In the topical composition of the present invention, the component (E) may be one selected from tocopherol and its derivatives, or two or more may be used in combination. Among the components (E), from the viewpoint of further improving the effect of improving inflammation of the skin after shaving, preferred are tocopherol derivatives, more preferred are esters of tocopherol with carboxylic acid, even more preferred are tocopherol acetate, and particularly preferred are d-α-tocopherol acetate, l-α-tocopherol acetate, and dl-α-tocopherol acetate.

[0037] When the topical composition of the present invention contains component (E), the content of component (E) is not particularly limited. From the viewpoint of further improving the effect of improving skin inflammation after shaving, the total amount of component (E) is, for example, 0.05 to 2 wt %, preferably 0.1 to 1.3 wt %, and more preferably 0.3 to 0.8 wt %.

[0038] Furthermore, when the topical composition of the present invention contains component (E), the ratio of component (E) to component (A) is determined based on the above-mentioned content range of each component. From the viewpoint of further improving the effect of improving skin inflammation after shaving, the total amount of component (E) per part by weight of component (A) is 0.01 to 1 part by weight, preferably 0.03 to 0.5 parts by weight, and more preferably 0.05 to 0.3 parts by weight.

[0039] (F) Antibacterial or disinfectant The topical composition of the present invention may further contain an antibacterial or bactericidal agent as component (F) from the viewpoint of further improving the effect of improving skin inflammation after shaving.

[0040] The antibacterial or bactericidal agent is not particularly limited, as long as it is pharmaceutically or cosmetically acceptable.For example, quaternary ammonium antibacterial agents, isopropylmethylphenol, hinokitiol, chlorhexidine hydrochloride, chlorhexidine gluconate, triclosan, lysozyme chloride, sulfazine, etc. are included.Specific examples of quaternary ammonium antibacterial agents include cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, dequalinium chloride, alkyldimethylammonium chloride, alkyltrimethylammonium chloride, methylbenzethonium chloride, lauroylcollaminoformylmethylpyridinium chloride, etc.

[0041] These antibacterial or bactericidal agents may be used alone or in combination of two or more.

[0042] Among these antibacterial or bactericidal agents, isopropyl methylphenol is preferable from the viewpoint of further improving the effect of improving skin inflammation after shaving.

[0043] When the topical composition of the present invention contains component (F), the content of component (F) may be appropriately set depending on the type of antibacterial or bactericidal agent used, and may be, for example, 0.01 to 1% by weight. From the viewpoint of further improving the effect of improving skin inflammation after shaving, the content of component (C) is preferably 0.03 to 0.5% by weight, and more preferably 0.05 to 0.3% by weight.

[0044] When the topical composition of the present invention contains component (F), the ratio of component (A) to component (F) is determined according to the respective contents of these two components described above, but for example, the ratio may be 0.001 to 0.5 parts by weight, preferably 0.005 to 0.1 parts by weight, and more preferably 0.01 to 0.05 parts by weight of component (F) per 1 part by weight of component (A).

[0045] Other Ingredients In addition to the above-mentioned components, the composition for external use of the present invention may contain other pharmacological components as necessary. Examples of such pharmacological components include antihistamines (chlorpheniramine maleate, etc.), local anesthetics (dibucaine, procaine, tetracaine, bupivacaine, mepivacaine, chloroprocaine, proparacaine, meprylcaine, or salts thereof), alkyl benzoates (e.g., ethyl aminobenzoate, diethylaminoethyl p-butylaminobenzoate hydrochloride), orthocaine, oxethazaine, oxypolyethyleneoxydecane, Scopolia extract, percaminpase, tesitdesitin, etc.), anti-inflammatory agents (allantoin , salicylic acid, glycol salicylate, methyl salicylate, indomethacin, felbinac, diclofenac sodium, loxoprofen sodium, etc.), antipruritic agents (crotamiton, thianthol, etc.), skin protectants (collodion, castor oil, etc.), blood circulation promoting ingredients (vanillyl nonyl amide, nicotinic acid benzyl ester, capsaicin, chili pepper extract, etc.), cooling agents (menthol, camphor, etc.), vitamins (vitamins A, B, C, D, etc.), mucopolysaccharides (sodium chondroitin sulfate, hyaluronic acid, etc.).

[0046] In addition to the above-mentioned components, other bases and additives that are usually used in skin external preparations and the like may be contained as necessary. Such bases and additives are not particularly limited as long as they are pharma- ceutically acceptable, and examples of such bases and additives include aqueous bases such as water, lower alcohols (e.g., isopropanol), and polyhydric alcohols (glycerin, propylene glycol, dipropylene glycol, 1,3-butylene glycol, etc.); oils (olive oil, safflower oil, soybean oil, camellia oil, corn oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, lard, squalane, fish oil, etc.), mineral oils (liquid paraffin, paraffin, gelling hydrocarbon, petrolatum, etc.), waxes (beeswax, carnauba wax, candelilla wax, ceresin, rice wax, microcrystalline wax, etc.), ester oils (isopropyl myristate, isopropyl adipate, etc.), and the like. oily bases such as diethyl sebacate, isopropyl sebacate, isopropyl palmitate, cetyl palmitate, ethyl oleate, etc., fatty acid alkyl esters, fatty acids (stearic acid, oleic acid, palmitic acid, behenic acid, linoleic acid, lanolin, etc.), fatty acid esters (cetyl palmitate, isopropyl palmitate, isopropyl myristate, ethyl linoleate, etc.), higher alcohols (stearyl alcohol, cetanol, behenyl alcohol, myristyl alcohol, oleyl alcohol, hexadecyl alcohol, lanolin alcohol, etc.), cholesterol, glyceryl tri-2-ethylhexanoate, cetyl 2-ethylhexanoate, silicone oil (dimethylpolysiloxane, cyclic silicone, etc.);Polyoxyethylene alkyl ethers such as POE (10-50 mol) phytosterol ether, POE (10-50 mol) dihydrocholesterol ether, POE (10-50 mol) 2-octyldodecyl ether, POE (10-50 mol) decyltetradecyl ether, POE (10-50 mol) oleyl ether, POE (2-50 mol) cetyl ether (cetomacrogol 1000, etc.), POE (5-50 mol) behenyl ether, POE (5-30 mol) polyoxypropylene (5-30 mol) 2-decyltetradecyl ether, POE (10-50 mol) polyoxypropylene (2-30 mol) cetyl ether, phosphoric acid salts thereof (e.g. sodium POE cetyl ether phosphate), POE (20-60 mol) sorbitan monooleate, POE (10-60 mol) sorbitan mono Surfactants such as isostearate, POE (10-80 mol) glyceryl monoisostearate, POE (10-30 mol) glyceryl monostearate, POE (20-100 mol)·polyoxypropylene modified silicone, POE·alkyl modified silicone, polyethylene glycol monolaurate, polyethylene glycol monopalmitate, polyethylene glycol monostearate, polyethylene glycol dilaurate, polyethylene glycol dipalmitate, polyethylene glycol distearate, polyethylene glycol dioleate, polyethylene glycol diricinoleate, polyoxyethylene hydrogenated castor oil (5-100), polysorbate (20-85), glycerin fatty acid ester (glycerin monostearate, etc.), hydrogenated soybean phospholipid, hydrogenated lanolin alcohol, etc.;Cooling agents (menthol, camphor, borneol, peppermint water, peppermint oil, etc.), preservatives (methylparaben, propylparaben, benzoic acid, sodium benzoate, sorbic acid, etc.), flavoring agents (citral, 1,8-thioneol, citronellal, farnesol, etc.), coloring agents (tar dyes (brown No. 201, blue No. 201, yellow No. 4, yellow No. 403, etc.), cacao dyes, chlorophyll, aluminum oxide, etc.), thickeners (carboxyvinyl polymer, hypromellose, polyvinylpyrrolidone, sodium alginate, ethyl cellulose, hydroxyethyl cellulose, sodium carboxymethylcellulose, xanthan gum, carrageenan, etc.), pH adjusters (phosphoric acid, hydrochloric acid, citric acid, chlosyl ester, ethyl cellulose ... Examples of additives include additives such as sodium enoate, succinic acid, tartaric acid, sodium hydroxide, potassium hydroxide, triethanolamine, triisopropanolamine, etc.), wetting agents (sodium dl-pyrrolidone carboxylate solution, D-sorbitol solution, macrogol, etc.), stabilizers (dibutylhydroxytoluene, butylhydroxyanisole, sodium edetate, sodium metaphosphate, L-arginine, L-aspartic acid, DL-alanine, glycine, sodium erythorbate, propyl gallate, sodium sulfite, sulfur dioxide, chlorogenic acid, catechin, rosemary extract, etc.), antioxidants, ultraviolet absorbers, chelating agents, adhesives, buffers, dissolution aids, solubilizers, and preservatives.

[0047] Properties, formulation, etc. The properties of the topical composition of the present invention are not particularly limited, and include aqueous liquid compositions, aqueous gel compositions, oily gel compositions, emulsion compositions, etc. Among these, from the viewpoint of further improving the effect of improving skin inflammation after shaving, preferably emulsion compositions are used. The emulsion state of the emulsion composition may be either oil-in-water type or water-in-oil type, but from the viewpoint of further improving the effect of improving skin inflammation after shaving, preferably oil-in-water type is used.

[0048] The formulation of the topical composition of the present invention is not particularly limited, and examples thereof include lotions, emulsions, ointments, creams, etc. Among these, from the viewpoint of further improving the effect of improving skin inflammation after shaving and from the viewpoint of ease of application, emulsions and creams are preferred.

[0049] Specific examples of the composition for external use of the present invention include medicines, quasi-drugs, cosmetics, etc. Among these preparation forms, medicines are preferred.

[0050] Purpose The topical composition of the present invention is used to improve inflammation of the skin after shaving. The site of inflammation to which the composition is applied is not particularly limited as long as the site has been shaved, but the topical composition of the present invention is particularly preferably applied to inflammation of the skin in the so-called delicate zones, namely the lower abdomen (V zone), the vulva (I zone), the buttocks, and / or the anus (O zone).

[0051] The form of skin inflammation is not particularly limited, but examples include pain (stinging sensation), rash, red bumps, etc. Furthermore, the present invention is preferably applicable to inflammation not accompanied by itching.

[0052] The topical composition of the present invention can be applied to skin suffering from post-shaving dermatitis by applying it 1 to 6 times a day. In order to more effectively improve the post-shaving skin inflammation, the topical composition of the present invention is preferably applied for, for example, 5 days or more, preferably 1 week or more. EXAMPLES

[0053] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0054] Test Example The topical composition shown in Table 1 was prepared as an oil-in-water emulsion composition (cream). The topical composition was applied to the affected area for one week (three times a day) for subjects (N=15) who had razor burn caused by shaving at least once a week, resulting in rash, redness, and stinging inflammation (all without itching) in the lower abdomen (V zone) and vulva (I zone). After one week, the satisfaction with the improvement of inflammation was evaluated using a five-level VAS (satisfied, slightly satisfied, neutral, slightly dissatisfied, dissatisfied), and the percentage (%) of the 15 subjects who answered "satisfied" was calculated as the "effectiveness rate." First, Comparative Examples 1 and 2 and Example 2 were tested, and then, after the symptoms caused by shaving recurred to the same extent as before the test, Comparative Examples 3 to 5 and Example 2 were tested. The results are shown in Table 1.

[0055] [Table 1]

[0056] As shown in Table 1, only a few subjects answered that they were satisfied with the topical composition of Comparative Example 1 containing only ufenamate as an active ingredient, and only a few answered that they were satisfied with the topical composition of Comparative Example 2 containing only lidocaine as an active ingredient, but the topical composition of Example 1 containing ufenamate and lidocaine showed a high effect of improving inflammation, with more than half of the subjects answering that they were satisfied. In addition, only a few subjects answered that they were satisfied with the topical composition of Comparative Example 3 containing diphenhydramine, glycyrrhetinic acid, tocopherol acetate, and isopropylmethylphenol, and even less than half of the subjects answered that they were satisfied with the topical compositions of Comparative Examples 4 and 5 containing ufenamate or lidocaine. On the other hand, the topical composition of Example 2 containing ufenamate and lidocaine together with diphenhydramine, glycyrrhetinic acid, tocopherol acetate, and isopropylmethylphenol showed an even higher effect of improving inflammation, with most of the subjects answering that they were satisfied.

[0057] [Prescription example] The topical compositions having the formulations shown in Table 2 were prepared as oil-in-water emulsion compositions (creams). All of the topical compositions showed excellent effects in improving skin inflammation after shaving.

[0058] [Table 2]

Claims

1. A topical composition for use in improving skin inflammation after shaving, comprising (A) ufenamate, (B) lidocaine and / or its salt, (C) glycyrrhetinic acid, a derivative of glycyrrhetinic acid, and / or their salts, (D) diphenhydramine and / or its salt, (E) tocopherol and / or its derivative, and (F) an antibacterial or bactericidal agent.

2. The topical composition according to claim 1 , which is applied to inflammation of the skin in the lower abdomen, vulva, and / or anal area.

3. The composition for external use according to claim 1 or 2, which is applied to inflammation not accompanied by itching.

Citation Information

Patent Citations

  • Ufenamate-containing skin care preparation

    JP2012136491A

  • Skin external composition

    JP2019099500A

  • Skin external composition

    JP2020033311A